skip to main content

Panic disorder with hormone-free-interval-associated symptom exacerbation — DFSRH MCQ

Instant feedback + full explanation. One question, done properly.

HardAnxietyPanic disorder with hormone-free-interval-associated symptom exacerbationDFSRH

A 29-year-old woman with panic disorder requests review of her contraception. Her symptoms have otherwise been stable for 12 months with cognitive behavioural therapy and sertraline. She has used a monophasic combined oral contraceptive containing 30 micrograms ethinylestradiol and 150 micrograms levonorgestrel in a 21/7 regimen for 10 months, with no missed tablets. During each of the past six cycles, she has developed marked anxiety, autonomic arousal and one or two panic attacks during days 4–7 of the hormone-free interval. Symptoms resolve within 48 hours of restarting active tablets and do not occur during active-tablet use. A prospective symptom diary confirms this pattern. Pregnancy testing, full blood count and thyroid function are normal, and she reports no stimulant or illicit drug use. She does not smoke, has a BMI of 23 kg/m² and normal blood pressure, and has no migraine with aura, cardiovascular disease or personal or family history of venous thromboembolism. She wishes to continue an oral contraceptive and is prepared to accept initial unscheduled bleeding. Which is the most appropriate management plan?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: C — Continue the current monophasic combined pill using a continuous regimen without scheduled intervals

Explanation lettering: D = shown as C · E = shown as D · C = shown as E

The reproducible timing, prospective diary and rapid resolution after restarting active tablets identify the hormone-free interval, rather than exposure to the active formulation, as the likely trigger for her symptom exacerbations. She remains medically eligible for combined hormonal contraception, takes it correctly and prefers an oral method. FSRH advises that tailored combined hormonal contraceptive regimens with fewer, shorter or no hormone-free intervals are safe and at least as effective as traditional 21/7 use. A monthly withdrawal bleed has no health benefit, and continuous use can reduce hormone-free-interval-associated symptoms, including mood change. Initial unscheduled bleeding should be anticipated and counselled about. A is inappropriate because scheduled benzodiazepine prophylaxis does not address the contraceptive trigger and NICE advises against benzodiazepines for panic disorder because of poorer long-term outcomes and dependence risk. B would remove the oestrogen-withdrawal interval and is plausible, but changing method is unnecessary when her current active tablets are well tolerated and continuous use directly addresses the temporal mechanism. C retains the seven-day withdrawal interval and merely increases oestrogen exposure. E provides effective non-hormonal contraception but disregards her preference and is not required in the absence of a combined-hormonal-contraception contraindication.

Reference: FSRH Guideline: Combined Hormonal Contraception (October 2023) — https://www.fsrh.org/Common/Uploaded%20files/documents/fsrh-guideline-combined-hormonal-contraception-october-2023.pdf Generalised anxiety disorder and panic disorder in adults: management (CG113) (Published 26 January 2011; last updated 15 June 2020) — https://www.nice.org.uk/guidance/cg113/chapter/Recommendations